BillionToOne (BLLN) vs Henry Schein (HSIC)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Henry Schein is the larger company by market cap ($9.40 billion vs $4.69 billion), about 2.0 times the size, while BillionToOne is growing revenue faster (+100.0% vs +4.0%). On valuation, Henry Schein trades at a lower forward P/E (14.1x vs 66.9x for BillionToOne). Henry Schein converts more of its revenue into profit, with a net margin of 3.0% versus 2.4%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | BLLN | HSIC |
|---|---|---|
| Share price | $99.34 | $84.34 |
| Market cap | $4.69B | $9.40B |
| 1-day change | +4.12% | -0.34% |
| YTD return | +16.58% | +11.97% |
| 1-year return | — | +30.74% |
| 5-year return | — | +9.28% |
| P/E ratio (TTM) | 157.68 | 24.59 |
| Forward P/E | 66.90 | 14.10 |
| EPS (TTM) | $0.63 | $3.43 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $305.11M | $13.18B |
| Revenue growth (YoY) | +99.97% | +4.03% |
| Net income (latest FY) | $7.45M | $398.00M |
| Gross margin | 68.32% | 31.14% |
| Operating margin | 5.25% | 4.95% |
| Net margin | 2.44% | 3.02% |
| 52-week high | $150.44 | $92.18 |
| 52-week low | $61.96 | $61.95 |
| Distance from 52-week high | -33.97% | -8.51% |
| Analyst consensus | strong_buy | buy |
| Avg. price target upside | +29.86% | +15.33% |
| Average volume | 689.14K | 1.22M |
| Shares outstanding | 42.64M | 111.45M |
| Employees | 713 | 25,000 |
| Sector | Health Care | Health Care |
| Industry | Medical Specialities | Medical Specialities |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- Henry Schein is about 2.0 times larger than BillionToOne by market value ($9.40B vs $4.69B).
- BillionToOne trades at a higher earnings multiple (157.7x vs 24.6x trailing P/E).
- BillionToOne grew revenue faster in its latest fiscal year (+99.97% vs +4.03%).
About BillionToOne
BLLN stock →BillionToOne, Inc., a precision diagnostics company, quantifies biology to create molecular diagnostics. The company provides molecular counting platform, which is designed to detect and measure DNA molecules at the single-count level to help enhance disease detection.
Health Care · Medical Specialities · 713 employees
About Henry Schein
HSIC stock →Henry Schein, Inc. provides health care products and services to office-based dental and medical practitioners worldwide.
Health Care · Medical Specialities · 25,000 employees
BLLN vs HSIC FAQ
Which is bigger, BillionToOne or Henry Schein?
Henry Schein (HSIC) is larger, with a market capitalization of $9.40B compared with $4.69B for BillionToOne (BLLN).
Which has the lower P/E ratio, BLLN or HSIC?
HSIC has the lower trailing P/E at 24.6, versus 157.7 for BLLN. A lower P/E is not by itself a sign of a better investment; it can reflect slower expected growth or higher risk.
Are BillionToOne and Henry Schein in the same industry?
Yes. Both are classified in the Medical Specialities industry within the Health Care sector.